Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
multi-antigen specific CAR T cells (Shenzhen Geno-Immune Medical Institute)
- Development stage
- Unknown
- Lead developer
- Shenzhen Geno-Immune Medical Institute
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
This investigational autologous CAR T-cell therapy, developed by the Shenzhen Geno-Immune Medical Institute (GIMI), is designed for the treatment of relapsed and refractory multiple myeloma. Utilizing the proprietary 4SCAR2.0 (fourth-generation safety-designed CAR) platform, the therapy involves the administration of T cells engineered to target multiple tumor-associated antigens, including B-cell maturation antigen (BCMA), CD38, CD138, and GPRC5D. This multi-target approach aims to mitigate tumor antigen escape, a common cause of relapse in single-target CAR T therapies. The 4SCAR2.0 construct incorporates a CD27 costimulatory domain to enhance cytokine signaling and immune memory, along with an inducible Caspase-9 safety mechanism that allows for the rapid elimination of CAR T cells in the event of severe toxicity, such as cytokine release syndrome (CRS).
- Other names
- Multi-CAR T cell therapy4SCAR2.0 CAR T cells
02
Targets
CD38 (Cluster of Differentiation 38)CASP9 (Caspase-9)GPRC5DSDC1 (Syndecan-1)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on multi-antigen specific CAR T cells (Shenzhen Geno-Immune Medical Institute).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on multi-antigen specific CAR T cells (Shenzhen Geno-Immune Medical Institute).